Skip to main content
. 2021 Jul 22;22(3):680. doi: 10.3892/ol.2021.12941

Figure 1.

Figure 1.

Synergistic cell proliferation inhibition by combined treatment with RCS and BTZ in CAL27 and Detroit562 cells. (A) CAL27 cells were treated with RCS (1, 2.5, 5 and 10 µM) with/without BTZ (2.5, 5 and 10 nM) for 24 and 48 h. Viable cell number was assessed by CellTiter Blue assay. (B) Synergistic effect of CAL27 cell proliferative inhibition was statistically analyzed using Combenefit software. Left: Mapping of the synergy levels on the experimental combination dose-response surface. Right: Synergy levels in matrix format. Higher score shown in denser blue indicates a stronger synergistic effect (C and D). n=3. Data are presented as the mean ± SD. *P<0.05 vs. BTZ 0 nM. Detroit562 cells were treated with RCS and BTZ, and the synergistic effect of cell growth inhibition was statistically analyzed as aforementioned. RCS, ricolinostat; BTZ, bortezomib.